Armistice Capital, LLC Trevi Therapeutics, Inc. Transaction History

Armistice Capital, LLC

  • $6.02 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$1.54 - $4.28 $689,920 - $1.92 Million
448,000 Added 107.69%
864,000 $1.33 Million
Q2 2022

Aug 15, 2022
BUY
$1.8 - $3.39 $748,800 - $1.41 Million
416,000 New
416,000 $1.17 Million
Q1 2022

May 16, 2022
SELL
$0.46 - $2.48 $695,678 - $3.75 Million
-1,512,344 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$0.68 - $1.5 $1.03 Million - $2.27 Million
1,512,344 New
1,512,344 $1.18 Million

Others Institutions Holding TRVI

# of Institutions
94
Shares Held
57.1M
Call Options Held
136K
Put Options Held
5.4K
View Full List

About Trevi Therapeutics, Inc.

TRVI Quotes by TradingView
  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $247M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email